Sozinibercept

• CAT Number: I042320
• CAS Number: 2568358-31-4
• Purity: ≥95%

Sozinibercept（Cat No.:I042320）is a novel, recombinant fusion protein developed to target vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), both of which are involved in angiogenesis, the process of new blood vessel formation. By inhibiting these factors, Sozinibercept aims to reduce abnormal blood vessel growth, which is crucial in conditions like age-related macular degeneration, diabetic retinopathy, and other ocular diseases. The compound has shown promise in preclinical and clinical studies for treating eye diseases that involve excessive angiogenesis.